BTL Marks a Milestone with One Million EMFACE Treatments and New Eye Procedure

BTL Achieves Over One Million EMFACE Treatments and Introduces EMFACE Eye

In a historic achievement, BTL, a renowned innovator in medical and aesthetic technology, has announced an impressive milestone: over one million EMFACE treatments performed worldwide. This significant landmark coincides with the launch of EMFACE Eye, the first-ever non-invasive procedure targeting under-eye aging, designed to restore muscle tone and enhance soft tissue support. This double success speaks volumes about BTL's pioneering role in the aesthetics industry.

BTL's innovative EMFACE technology has rapidly gained traction, emerging as the leading solution in facial aesthetic treatments. The company reported a remarkable 70% growth in Q1 2025 sales across North America, marking it as one of the most successful periods in its history. "The overwhelming response to EMFACE has been nothing short of extraordinary," stated David Chmel, BTL's CEO. He further emphasized, "Reaching the one million treatment mark highlights the trust our providers hold in BTL and our commitment to propelling forward innovations in non-invasive aesthetics."

The newly released EMFACE Eye treatment effectively addresses several concerns within the delicate under-eye region, which has historically been challenging to treat. Traditional methods often depended on surgical interventions or injectables to tackle issues such as puffiness, dark circles, and hollowness. In contrast, EMFACE Eye offers a revolutionary alternative that specifically tones the lower orbicularis oculi muscle, lifts soft tissue, and boosts periorbital support, all without any needles.

During a short, 20-minute session, patients can achieve significant enhancements, including an average decrease of 1.4mL in eye bag volume, a 28% reduction in crow's feet, and an impressive 64% decrease in visible dark circles. These results are clinically supported and do not require any recovery time, making it a substantial benefit to both healthcare practitioners and their clients.

Dr. Melanie Palm, a prominent cosmetic dermatologist from Solana Beach, CA, lauded the introduction of EMFACE Eye, stating, "As a cosmetic dermatologist with a significant injectable clientele, this treatment is a game-changer. Not only does it noticeably brighten the under-eye area, but it also strengthens the infraorbital fat pad, effectively reducing the appearance of fat pseudo-herniation."

The EMFACE technology restores natural structure and function to facial anatomy, promising outstanding outcomes that cater to high patient satisfaction levels. With the addition of the new Eye applicators, the comprehensive EMFACE platform enables full-face balancing, enhancing various facial segments from forehead lifting to jawline definition and under-eye rejuvenation. This multilayered approach integrates seamlessly with injectable treatments, ensuring a naturally harmonious aesthetic result.

About BTL

Established in 1993, BTL has positioned itself as a global frontrunner in medical device innovation, offering groundbreaking solutions in several fields, including dermatology, plastic surgery, and rehabilitative care. With over 200 patents and a robust team of more than 500 engineers, BTL continuously leverages advanced technologies to enhance medical treatments and patient care. Its expansive portfolio includes products such as EMSCULPT NEO®, EMFACE®, and EMSELLA®. To learn more about BTL, visit www.bodybybtl.com.